The c-MET proto-oncogene encodes a transmembrane receptor tyrosine kinase (TK) – the receptor for hepatocyte growth factor (HGF). Abnormal c-MET activation in cancer correlates with poor prognosis, where aberrantly active MET triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). MET is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. 

Germline mutations in the tyrosine kinase domain of MET occur in 100% of hereditary papillary renal cell carcinoma, and somatic mutations in MET are found in 10–15% of sporadic papillary renal cell carcinoma. Mutations in MET have been reported at low frequencies in head and neck squamous cell carcinoma, childhood hepatocellular carcinoma, NSCLC, and small cell lung cancer. Amplification of MET has been reported in gastric cancer, esophageal cancer, colorectal cancer, gliomas, clear cell ovarian cancer, and NSCLC. 

Empire Genomics has developed a custom c-MET probe which can be used to detect/confirm a rearrangement of the c-MET gene. The probe comes labeled in orange and generally ships within 24 hours. You can choose to customize the probe to meet your needs, which will ship right after production of the probe is complete (approximately 1 week).

Probe Details

Gene:	c-MET (Orange 5-TAMRA dUTP)
Loci:	7q31.2
Test Kits:	20

 

The leading supplier of molecular diagnostics for customization and production of FISH probes, aGCH assays and upcoming new technologies to be used by Reference labs, Academic labs, Pharma, CRO’s
and Pharma /Biotech companies around the world.

Our companion Diagnostics will allow you to :
-Validate Bio-markers (signature identification and resistance).
-Identify and qualify the aberration at the Chromosomal level of specific population.
-Follow up the result of therapeutic treatment (monitoring, compound profiling, drug response, patient stratification and safety)
-Compare with the result of your current technology.
-Be translated into the initial phase of your diagnostics development toward new FDA filings (pre-clinical through clinical trial development).